|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-8-2
|
|
pubmed:abstractText |
HIV infection leads to decreases in the number of CD4 T lymphocytes and an increased risk for opportunistic infections and neoplasms. The administration of intermittent cycles of IL-2 to HIV-infected patients can lead to profound increases (often greater than 100%) in CD4 cell number and percentage. Using in vivo labeling with 2H-glucose and BrdU, we have been able to demonstrate that, although therapy with IL-2 leads to high levels of proliferation of CD4 as well as CD8 lymphocytes, it is a remarkable preferential increase in survival of CD4 cells (with half-lives that can exceed 3 years) that is critical to the sustained expansion of these cells. This increased survival was time-dependent: the median half-life, as determined by semiempirical modeling, of labeled CD4 cells in 6 patients increased from 1.7 weeks following an early IL-2 cycle to 28.7 weeks following a later cycle, while CD8 cells showed no change in the median half-life. Examination of lymphocyte subsets demonstrated that phenotypically naive (CD27+CD45RO-) as well as central memory (CD27+CD45RO+) CD4 cells were preferentially expanded, suggesting that IL-2 can help maintain cells important for host defense against new antigens as well as for long-term memory to opportunistic pathogens.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-10068580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-10371571,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-10537110,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-10889591,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-10915072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-11465092,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-11531952,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-11564594,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-11696593,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-11748275,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-11943448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-12004267,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-12149467,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-12413877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-12496379,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-12556688,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-12692546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-14600575,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-14640722,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-15090457,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-1564090,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-8857018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-9142122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16025158-9883844
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0021-9738
|
|
pubmed:author |
pubmed-author:AdelsbergerJoseph WJW,
pubmed-author:BaselerMichael WMW,
pubmed-author:BoscheMarjorieM,
pubmed-author:DaveyRichard TRTJr,
pubmed-author:Di MascioMicheleM,
pubmed-author:DimitrovDimiter SDS,
pubmed-author:FalloonJudithJ,
pubmed-author:FoxStephen DSD,
pubmed-author:HosackDouglas ADA,
pubmed-author:IssaqHaleem JHJ,
pubmed-author:KellyGraceG,
pubmed-author:KovacsJoseph AJA,
pubmed-author:LambertLaurieL,
pubmed-author:LaneH CliffordHC,
pubmed-author:LeitmanSusanS,
pubmed-author:LempickiRichard ARA,
pubmed-author:MasurHenryH,
pubmed-author:MetcalfJulia AJA,
pubmed-author:PolisMichael AMA,
pubmed-author:SachauWilliamW,
pubmed-author:SeretiIriniI,
pubmed-author:SidorovIgor AIA,
pubmed-author:StevensRandyR,
pubmed-author:TavelJorgeJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2139-48
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16025158-Adult,
pubmed-meshheading:16025158-Antigens, CD27,
pubmed-meshheading:16025158-Antigens, CD45,
pubmed-meshheading:16025158-CD4-CD8 Ratio,
pubmed-meshheading:16025158-CD4-Positive T-Lymphocytes,
pubmed-meshheading:16025158-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16025158-Cell Proliferation,
pubmed-meshheading:16025158-Cell Survival,
pubmed-meshheading:16025158-Female,
pubmed-meshheading:16025158-HIV,
pubmed-meshheading:16025158-HIV Infections,
pubmed-meshheading:16025158-Humans,
pubmed-meshheading:16025158-Immunologic Memory,
pubmed-meshheading:16025158-Interleukin-2,
pubmed-meshheading:16025158-Male,
pubmed-meshheading:16025158-Middle Aged,
pubmed-meshheading:16025158-Opportunistic Infections,
pubmed-meshheading:16025158-T-Lymphocyte Subsets
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients.
|
|
pubmed:affiliation |
Critical Care Medicine Department, Warren G. Magnuson Clinical Center, NIH, Bethesda, Maryland, USA. jkovacs@niaid.nih.gov
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, N.I.H., Extramural
|
